Physician profile
Irwin T Leventhal
NPI 1386710192
$2,751.14
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $448 · 2021: $622 · 2022: $674 · 2023: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $235.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $666.77 | 2019-2023 | Myrbetriq, Xtandi |
| Janssen Biotech, INC. | $446.44 | 2019-2023 | Erleada |
| Pfizer INC. | $435.82 | 2019-2023 | |
| Urovant Sciences INC | $188.87 | 2021-2022 | |
| Abbvie INC. | $169.35 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.88 | 2019-2023 | |
| Blue Earth Diagnostics | $153.16 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $130.21 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $95.63 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $67.73 | 2020-2023 | Lynparza, Keytruda |
| Zyla Life Sciences, INC. | $65.52 | 2020 | |
| Myovant Sciences INC. | $23.95 | 2021 | |
| Sumitomo Pharma America, INC. | $23.45 | 2023 | Gemtesa |
| Endo Pharmaceuticals INC. | $23.05 | 2019 | |
| Clarus Therapeutics INC. | $21.50 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $20.80 | 2023 | |
| Allergan, INC. | $20.00 | 2019 | |
| Coloplast Corp | $18.36 | 2019 | |
| Progenics Pharmaceuticals, INC. | $16.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irwin Leventhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.